Cure My Disease

Don't miss your cure!

 Log in / Sign up

Engineered immune cells take on post-transplant virus in early trial

NCT ID NCT06119256

Recruiting now Disease control Sponsor: Chinese PLA General Hospital Source: ClinicalTrials.gov ↗

First seen Apr 03, 2026 · Last updated May 15, 2026 · Updated 4 times

Summary

This early-phase study tests whether specially designed immune cells (EBV-TCR-T cells) can safely control Epstein-Barr virus (EBV) infections in people who have had a stem cell transplant for blood cancer. About 12 participants aged 14 to 75 will receive the cells and be monitored for side effects and changes in virus levels. The goal is to manage the infection, not to cure the underlying disease.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EBV INFECTION AFTER ALLOGENIC HSCT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-••••

Locations

  • Chinese PLA General Hospital

    RECRUITING

    Beijing, Beijing Municipality, 100853, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

EBV INFECTION AFTER ALLOGENIC HSCT